ReviewMediators of inflammation2026
Current Progress in the Role of Ferroptosis in Skeletal Muscle Atrophy.
Review in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Vulnerability and Regenerative Failure of the External Urethral Sphincter: A Ferroptosis-Associated Framework for Stress Urinary Incontinence.Biomolecules · 2026Review
- Ferroptosis in skeletal muscle: from molecular mechanisms to therapeutic interventions.Journal of orthopaedic translation · 2026Review
- Current Progress in the Role of Ferroptosis in Skeletal Muscle Atrophy.Mediators of inflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrophy of skeletal muscles, caused by multiple factors, including ageing, disuse, trauma and systemic diseases, is a major pathological condition that affects physical performance and systemic health by the loss of muscle function; in effect, weakening the whole body and leading to disabling conditions such as sarcopenia, frailty and increased fall risk. First reported in 2012 by Dixon et al., ferroptosis is a newly identified, distinct type of regulated cell death characterised by unique biochemical and morphological features and differs from classic apoptosis and necrosis. One hallmark feature of ferroptosis is its iron-dependence: excessive free intracellular iron deposits catalyse rapid peroxidation of membrane lipids, and release cytotoxic lipid peroxides, which interfere with cell integrity. In recent years, significant progress has been made in elucidating the roles of ferroptosis-related pathways in skeletal muscle atrophy. Building on these advances, our review systematizes skeletal muscle atrophy into three significant categories: ageing-, disuse- and systemic disease-induced atrophy. It carefully explores the involvement of ferroptosis in each of these atrophy models. Moreover, this review identifies and discusses key ferroptosis-related molecular targets for consideration, aiming to provide insights and possible future directions for developing therapies to treat muscle-wasting disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.